8-K: Veru Inc. Announces Fiscal 2024 Second Quarter Results and Provides Update on Enobosarm Clinical Program

Veru Inc. reported its fiscal 2024 second quarter financial results and provided an update on the progress of its enobosarm clinical program for high quality weight loss.

Summary

• Veru Inc. announced its financial results for the second quarter of fiscal year 2024, which ended March 31, 2024.
• The company's net revenues decreased to $4.1 million from $6.6 million compared to the same quarter last year.
• Gross profit also decreased to $0.7 million from $4.1 million year-over-year.
• However, research and development expenses significantly decreased to $3.0 million from $17.9 million, and selling, general, and administrative expenses decreased to $7.6 million from $12.8 million.
• The operating loss improved to $9.9 million compared to $34.4 million in the prior year.
• Net loss was $10.0 million, or $0.07 per share, compared to a net loss of $33.8 million, or $0.42 per share, in the same quarter of the previous year.
• The company's cash and cash equivalents increased to $34.7 million as of March 31, 2024, from $9.6 million as of September 30, 2023.
• Veru is actively enrolling patients in a Phase 2b clinical trial for enobosarm in combination with semaglutide for high quality weight loss.
• Topline results from the Phase 2b clinical trial are expected by the end of calendar year 2024, with results from the extension study expected in Q2 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the improved financial results, progress in the enobosarm clinical trial, and the formation of a Scientific Advisory Board. However, the company is still operating at a loss and faces risks, which tempers the overall sentiment.

Positives

• The company's operating loss significantly decreased year-over-year, indicating improved financial performance.
• Net loss per share improved substantially compared to the same quarter last year.
• Cash and cash equivalents increased significantly, providing a stronger financial position.
• The Phase 2b clinical trial for enobosarm is actively enrolling patients, showing progress in the company's drug development program.
• The formation of a Scientific Advisory Board with five medical experts is a positive step for the enobosarm program.
• Research and development expenses have decreased significantly, which may indicate improved efficiency.

Negatives

• Net revenues decreased compared to the same quarter last year.
• Gross profit decreased compared to the same quarter last year.
• The company is still operating at a loss, although the loss has decreased.

Risks

• The success of the enobosarm clinical trial is not guaranteed, and results may not meet expectations.
• The company's ability to fund planned clinical development and operations is subject to risks.
• There are risks associated with the commercial success of any future products, if approved.
• The company faces competition from other pharmaceutical companies.
• There are risks related to the company's reliance on international partners and government spending.
• The company's production capacity and supply chain are subject to potential disruptions.
• The company is subject to litigation risks, including product liability claims and securities litigation.

Future Outlook

The company expects topline results from the Phase 2b clinical trial by the end of calendar year 2024 and topline results from the extension study in calendar Q2 2025. The company is focused on developing enobosarm for high quality weight loss and is also pursuing other drug development programs.

Management Comments

• Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc., stated that they are pleased to have initiated the Phase 2b enobosarm clinical trial.
• Dr. Steiner also mentioned that there is a significant unmet medical need for a drug that can preserve muscle and augment fat loss in patients receiving GLP-1 drugs for weight loss.
• Dr. Steiner expressed pleasure in assembling an esteemed group of five medical experts for their high quality weight loss Scientific Advisory Board.

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly in the areas of obesity and metabolic diseases. The development of enobosarm as a potential treatment to preserve muscle while augmenting fat loss in patients receiving GLP-1 drugs addresses a significant unmet medical need. The company is positioning itself in the competitive weight loss market, which is currently dominated by GLP-1 receptor agonists.

Comparison to Industry Standards

• Veru's approach of combining enobosarm with GLP-1 RAs is unique compared to companies solely focused on GLP-1 therapies like Novo Nordisk (Wegovy) and Eli Lilly (Zepbound).
• The focus on muscle preservation differentiates Veru from other weight loss drug developers, addressing a key concern with GLP-1 therapies.
• The company's clinical trial design, including the extension study, is aimed at demonstrating the long-term benefits of enobosarm in maintaining muscle mass after discontinuing GLP-1 RAs, which is not a standard focus in most weight loss trials.
• The company's financial results show a significant reduction in operating losses, which is a positive sign compared to other biotech companies in the development stage.

Stakeholder Impact

• Shareholders may be positively impacted by the improved financial results and progress in the enobosarm clinical trial.
• Employees may be positively impacted by the company's progress and financial stability.
• Patients may benefit from the development of enobosarm as a potential treatment for high quality weight loss.
• The company's suppliers and partners may be impacted by the company's financial performance and drug development progress.

Next Steps

• Continue enrolling patients in the Phase 2b clinical trial for enobosarm.
• Complete the Phase 2b clinical trial and analyze the topline results.
• Initiate the Phase 2b extension clinical trial.
• Present at the American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit.
• Continue to develop enobosarm for high quality weight loss and other indications.

Key Dates

Keywords

enobosarm, weight loss, sarcopenic obesity, GLP-1 RA, clinical trial, biopharmaceutical, muscle preservation, fat loss, financial results, VERU